Effective pharmacological neuroprotection is one of the most desired aims in modern medicine. We postulated that a combination of two clinically used drugs—nimodipine (L-Type voltage-gated calcium channel blocker) and amiloride (acid-sensing ion channel inhibitor)—might act synergistically in an experimental model of ischaemia, targeting the intracellular rise in calcium as a pathway in neuronal cell death. We used organotypic hippocampal slices of mice pups and a well-established regimen of oxygen-glucose deprivation (OGD) to assess a possible neuroprotective effect. Neither nimodipine (at 10 or 20 µM) alone or in combination with amiloride (at 100 µM) showed any amelioration. Dissolved at 2.0 Vol.% dimethyl-sulfoxide (DMSO), the combination of both components even increased cell damage (p = 0.0001), an effect not observed with amiloride alone. We conclude that neither amiloride nor nimodipine do offer neuroprotection in an in vitro ischaemia model. On a technical note, the use of DMSO should be carefully evaluated in neuroprotective experiments, since it possibly alters cell damage.
CITATION STYLE
Ort, J., Kremer, B., Grüßer, L., Blaumeiser-Debarry, R., Clusmann, H., Coburn, M., … Lindauer, U. (2020). Failed neuroprotection of combined inhibition of l-type and asic1a calcium channels with nimodipine and amiloride. International Journal of Molecular Sciences, 21(23), 1–17. https://doi.org/10.3390/ijms21238921
Mendeley helps you to discover research relevant for your work.